Addex Therapeutics (0QNV) AI Stock Analysis

Addex Therapeutics

(LSE:0QNV)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Low leverageVery low leverage reduces fixed financial obligations and near-term solvency pressure while the company funds clinical development. This gives Addex more flexibility to pursue partnerships, milestones, and pipeline decisions without the additional constraint of substantial debt service.

Negative Factors

Deep, persistent unprofitabilitySevere and continuing losses show that the current clinical-stage model has not yet produced economically sustainable earnings. Without approved products or dependable collaboration income, ongoing deficits can erode equity and increase reliance on future financing or strategic transactions.

Addex Therapeutics (0QNV) vs. iShares MSCI United Kingdom ETF (EWC)

Market Cap: CHF 2.88M
Dividend Yield: ―
Average Volume (3M): 285.49K
Price to Earnings (P/E): -0.5
Beta (1Y): 0.02
Revenue Growth: -50.34%
EPS Growth: 4.75%
Country: UK
Employees: 3
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Addex Therapeutics Business Overview & Revenue Model

Company Description

Addex Therapeutics Ltd, a biopharmaceutical company in its development phase, specializes in the discovery, progression, and commercialization of small-molecule pharmaceutical products designed to address central nervous system (CNS) conditions. Base...

Addex Therapeutics Earnings Call Summary

Earnings Call Date:Sep 27, 2026(Q2-2026)|% Change Since:-8.33%|Next Earnings Date:May 19, 2020

Earnings Call SentimentPositive

The call was predominantly positive, with management highlighting $2.8 million of financing, a cash runway into Q4 2027, regained rights to the GABAB PAM platform, strong preclinical chronic cough data, and continued progress across the Neurosterix and Addex pipelines. Offsetting factors included the CHF 0.8 million half-year cash balance, CHF 1.2 million of operating cash usage, continued net losses, an increase in Addex's share of Neurosterix's loss, and the need to secure financing before starting chronic cough IND-enabling studies.

Positive Updates

ATM Financing and Extended Cash Runway

Addex raised $2.8 million through its ATM facility in Q3 2026, strengthening the balance sheet and providing cash runway into Q4 2027.

Negative Updates

Limited Cash Balance at Half-Year

Addex ended H1 2026 with CHF 0.8 million in cash, down CHF 0.8 million from CHF 1.6 million as of December 31, 2026, primarily due to operating costs and partially offset by the sale of treasury ADSs.

Company Guidance

Addex said it has $2.8 million raised through its ATM facility and now has a cash runway through into Q4 of 2027; it expects NTX-253 to complete phase I very soon and expects phase I data from the NTX-253 program in Q4 this year, while NTX-529 IND-enabling studies should start shortly and NTX-819 is expected to complete IND-enabling studies in the coming months. The next milestone for the SUD program is the filing of an IND, and for the cough program, the start of IND-enabling studies, which are planned and ready to start subject to securing financing. Addex is also preparing dipraglurant for phase II in post-stroke recovery, and said it is looking forward to completing the evaluation of potential indications for its mGlu2 PAM program and securing the financial resources to advance its portfolio into clinical studies.

Addex Therapeutics Risk Analysis

Addex Therapeutics disclosed 54 risk factors in its most recent earnings report. Addex Therapeutics reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

1 New Risk

1.We were an "emerging growth company" for the financial reporting published until December 31, 2025 and it is possible that investors have found or will continue to find shares or our ADSs less attractive.Q4, 2025

Addex Therapeutics Peers Comparison

Overall Rating

Financial Indicators

GB:0QNV against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

GB:0QNV and its peers over the selected period
Show on chart	Ticker	Company Name	Price	Change	% Change
	GB:0QNV	Addex Therapeutics Ltd	0.02	-0.04	-64.52%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Addex Therapeutics AI Stock Analysis